PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
New hope for men with prostate cancer
"Football for Metastatic Prostate Cancer?!” - See page 3
If this were true, and patients were delaying screenings or treatments for cancer, it could impact their survival.
In the US, Black men are more likely than White men to die from prostate cancer.
Learn about the results of the phase 3 VISION clinical trial
A protein has been identified that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
Addressing the Genetics Debate Over Race, Ethnicity and Disparity Outcomes for Men With Prostate Cancer
There are assumptions that genetics somehow play a big role in poor outcomes in prostate cancer, even for patients diagnosed with similar stage disease.https://dailynews.ascopubs.org/do/10.1200/ADN.21.200582/full/?cid=DM7759&bid=82186533&
Tell your doctor if you are taking finasteride or any other hair loss prevention products.
Routine Screening Rates for Breast, Colorectal, and Prostate Cancers Decline During COVID-19 Pandemic
By causing cancellations of appointments and cancer screenings, COVID will indirectly cause an increase in cancer deaths—another negative consequence of COVID that has not yet received much public attention.
Is this the new normal?